Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
出版年份 2020 全文链接
标题
Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
作者
关键词
-
出版物
ADVANCES IN THERAPY
Volume 37, Issue 11, Pages 4697-4708
出版商
Springer Science and Business Media LLC
发表日期
2020-09-25
DOI
10.1007/s12325-020-01498-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
- (2019) Peter J. Eddowes et al. GASTROENTEROLOGY
- Fat and Fibrosis: Does Empagliflozin Impair the Progression of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus?
- (2019) Reenam S. Khan et al. DIGESTIVE DISEASES AND SCIENCES
- Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
- (2019) Lee-Lee Lai et al. DIGESTIVE DISEASES AND SCIENCES
- SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
- (2019) Naser Eddin Gharaibeh et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
- (2019) Sabine Kahl et al. DIABETES CARE
- Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes
- (2019) Laleh Razavi-Nematollahi et al. Current Diabetes Reports
- 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus
- (2018) Noboru Kurinami et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2018) Masanori Shimizu et al. DIABETES OBESITY & METABOLISM
- Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
- (2018) Norbert Stefan et al. Lancet Diabetes & Endocrinology
- Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
- (2018) Teruki Miyake et al. Open Medicine
- Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
- (2017) Akio Ohta et al. EXPERT OPINION ON PHARMACOTHERAPY
- Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
- (2017) Yuya Seko et al. JOURNAL OF GASTROENTEROLOGY
- Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
- (2017) Yong-ho Lee et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan
- (2017) Dominique Roulot et al. LIVER INTERNATIONAL
- Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study
- (2017) Yi-Hao Yen et al. PLoS One
- Clinical relevance of dual-energy X-ray absorptiometry (DXA) as a simultaneous evaluation of fatty liver disease and atherosclerosis in patients with type 2 diabetes
- (2016) Ryotaro Bouchi et al. Cardiovascular Diabetology
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
- (2016) Simon A. Hawley et al. DIABETES
- Effect of canagliflozin on liver function tests in patients with type 2 diabetes
- (2016) L.A. Leiter et al. DIABETES & METABOLISM
- Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks
- (2016) Lawrence Blonde et al. POSTGRADUATE MEDICINE
- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
- (2015) Mattias Ekstedt et al. HEPATOLOGY
- High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
- (2015) Paola Portillo-Sanchez et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures
- (2010) Seyed-Moayed Alavian et al. LIVER INTERNATIONAL
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
- (2010) Giovanni Targher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Controlled Attenuation Parameter (CAP): A Novel VCTE™ Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes
- (2010) Magali Sasso et al. ULTRASOUND IN MEDICINE AND BIOLOGY
- Magnetic Resonance Elastography for the Noninvasive Staging of Liver Fibrosis
- (2008) Laurent Huwart et al. GASTROENTEROLOGY
- Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes
- (2008) Anna Ludovica Fracanzani et al. HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now